國立虎尾科技大學 |

3D Printing of Pharmaceuticals

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	3D Printing of Pharmaceuticals/ edited by Abdul W. Basit, Simon Gaisford.
其他作者:	Basit, Abdul W.
面頁冊數:	XI, 240 p. 116 illus., 105 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmaceutical technology. -
電子資源:	https://doi.org/10.1007/978-3-319-90755-0
ISBN:	9783319907550

3D Printing of Pharmaceuticals
3D Printing of Pharmaceuticals[electronic resource] /edited by Abdul W. Basit, Simon Gaisford. - 1st ed. 2018. - XI, 240 p. 116 illus., 105 illus. in color.online resource. - AAPS Advances in the Pharmaceutical Sciences Series,312210-7371 ;. - AAPS Advances in the Pharmaceutical Sciences Series,20.

Paradigm of personalised medicines -- Pharmaceutical ink-jet printing -- Fused-deposition modelling (FDM) 3D printing -- Stereolithographic (SLA) 3D printing -- Selective laser sintering (SLS) 3D printing -- Flexographic 3D printing -- Semi-solid extrusion 3D printing -- Ink-jet printing for personalised dosing -- Printing crystal forms -- Printing of nanoparticle/polymer conjugates -- 3D Printing organ vasculature -- 3D printed ears -- Visualisation of 3D printed compartmental DDSs -- 3D printed medicines - A regulatory perspective -- Spritam – a case study -- 4D printing -- 3DP – costs and manufacturing issues -- Other non-pharmaceutical 3DP areas.

3D printing is forecast to revolutionise the pharmaceutical sector, changing the face of medicine development, manufacture and use. Potential applications range from pre-clinical drug development and dosage form design through to the fabrication of functionalised implants and regenerative medicine. Within clinical pharmacy practice, printing technologies may finally lead to the concept of personalised medicines becoming a reality. This volume aims to be the definitive resource for anyone thinking of developing or using 3D printing technologies in the pharmaceutical sector, with a strong focus on the translation of printing technologies to a clinical setting. This text brings together leading experts to provide extensive information on an array of 3D printing techniques, reviewing the current printing technologies in the pharmaceutical manufacturing supply chain, in particular, highlighting the state-of-the-art applications in medicine and discussing modern drug product manufacture from a regulatory perspective. This book is a highly valuable resource for a range of demographics, including academic researchers and the pharmaceutical industry, providing a comprehensive inventory detailing the current and future applications of 3D printing in pharmaceuticals. Professor Abdul Basit is a Professor of Pharmaceutics at the UCL School of Pharmacy, University College London. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. His research has been translated into the design of new technologies and improved disease treatments, many of which have been commercialised. Abdul is also a serial entrepreneur and has filed multiple patents, is the recepient of several research awards and has founded 3 companies (Kuecept, Intract Pharma, FabRx). He further serves as a consultant to many pharmaceutical organisations and is on the advisory boards of scientific journals, healthcare and charitable bodies. Professor Simon Gaisford holds a Chair in Pharmaceutics and is Head of the Department of Pharmaceutics at the UCL School of Pharmacy, University College London. He has published 110 papers, 8 book chapters, 4 authored books and is the recipient of multiple research awards. His research is focused on novel technologies for manufacturing medicines, particularly using ink-jet printing and 3D printing, translating his expertise by co-founding FabRx. Simon is also an expert in the physicochemical characterisation of compounds and formulations with thermal methods and calorimetry.

ISBN: 9783319907550

Standard No.: 10.1007/978-3-319-90755-0doiSubjects--Topical Terms:

557391
Pharmaceutical technology.

LC Class. No.: RS380

Dewey Class. No.: 615.19

3D Printing of Pharmaceuticals
LDR:04733nam a22004215i 4500 001 987855
003 DE-He213
005 20200705081550.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319907550 $9 978-3-319-90755-0
024 7 $a 10.1007/978-3-319-90755-0 $2 doi
035 $a 978-3-319-90755-0
050 4 $a RS380
050 4 $a RS190-210
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a TDC $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a 3D Printing of Pharmaceuticals $h [electronic resource] / $c edited by Abdul W. Basit, Simon Gaisford.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a XI, 240 p. 116 illus., 105 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 31
505 0 $a Paradigm of personalised medicines -- Pharmaceutical ink-jet printing -- Fused-deposition modelling (FDM) 3D printing -- Stereolithographic (SLA) 3D printing -- Selective laser sintering (SLS) 3D printing -- Flexographic 3D printing -- Semi-solid extrusion 3D printing -- Ink-jet printing for personalised dosing -- Printing crystal forms -- Printing of nanoparticle/polymer conjugates -- 3D Printing organ vasculature -- 3D printed ears -- Visualisation of 3D printed compartmental DDSs -- 3D printed medicines - A regulatory perspective -- Spritam – a case study -- 4D printing -- 3DP – costs and manufacturing issues -- Other non-pharmaceutical 3DP areas.
520 $a 3D printing is forecast to revolutionise the pharmaceutical sector, changing the face of medicine development, manufacture and use. Potential applications range from pre-clinical drug development and dosage form design through to the fabrication of functionalised implants and regenerative medicine. Within clinical pharmacy practice, printing technologies may finally lead to the concept of personalised medicines becoming a reality. This volume aims to be the definitive resource for anyone thinking of developing or using 3D printing technologies in the pharmaceutical sector, with a strong focus on the translation of printing technologies to a clinical setting. This text brings together leading experts to provide extensive information on an array of 3D printing techniques, reviewing the current printing technologies in the pharmaceutical manufacturing supply chain, in particular, highlighting the state-of-the-art applications in medicine and discussing modern drug product manufacture from a regulatory perspective. This book is a highly valuable resource for a range of demographics, including academic researchers and the pharmaceutical industry, providing a comprehensive inventory detailing the current and future applications of 3D printing in pharmaceuticals. Professor Abdul Basit is a Professor of Pharmaceutics at the UCL School of Pharmacy, University College London. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. His research has been translated into the design of new technologies and improved disease treatments, many of which have been commercialised. Abdul is also a serial entrepreneur and has filed multiple patents, is the recepient of several research awards and has founded 3 companies (Kuecept, Intract Pharma, FabRx). He further serves as a consultant to many pharmaceutical organisations and is on the advisory boards of scientific journals, healthcare and charitable bodies. Professor Simon Gaisford holds a Chair in Pharmaceutics and is Head of the Department of Pharmaceutics at the UCL School of Pharmacy, University College London. He has published 110 papers, 8 book chapters, 4 authored books and is the recipient of multiple research awards. His research is focused on novel technologies for manufacturing medicines, particularly using ink-jet printing and 3D printing, translating his expertise by co-founding FabRx. Simon is also an expert in the physicochemical characterisation of compounds and formulations with thermal methods and calorimetry.
650 0 $a Pharmaceutical technology. $3 557391
650 0 $a Biomedical engineering. $3 588770
650 1 4 $a Pharmaceutical Sciences/Technology. $3 768561
650 2 4 $a Biomedical Engineering/Biotechnology. $3 1068811
700 1 $a Basit, Abdul W. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1208071
700 1 $a Gaisford, Simon. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 583530
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319907543
776 0 8 $i Printed edition: $z 9783319907567
776 0 8 $i Printed edition: $z 9783030080914
830 0 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 20 $3 1255084
856 4 0 $u https://doi.org/10.1007/978-3-319-90755-0
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)